CompletedPhase 2NCT01685801

Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function

Studying Cystic fibrosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vertex Pharmaceuticals Incorporated
Principal Investigator
Jerry Nick, MD
National Jewish Health
Intervention
Ivacaftor(drug)
Enrollment
24 enrolled
Eligibility
12 years · All sexes
Timeline
20122014

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01685801 on ClinicalTrials.gov

Other trials for Cystic fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Cystic fibrosis

← Back to all trials